Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Endocrinology

Treating the Metabolic Fallout of AGL

At a Glance

The primary treatment for the metabolic complications of Acquired Generalized Lipodystrophy (AGL) is metreleptin, a daily hormone replacement injection. Metreleptin helps control severe hunger, lower blood sugar, and reduce triglycerides, protecting organs from long-term damage.

Managing Acquired Generalized Lipodystrophy (AGL) requires a two-pronged approach: protecting your organs from the immediate dangers of metabolic “overload” and, when possible, addressing the underlying cause of the fat loss.

The Foundation of Care: Hormone Replacement

The gold standard for treating the metabolic complications of AGL is metreleptin (brand name Myalept). Because AGL causes a near-total loss of fat tissue, your body stops producing leptin, a vital hormone that regulates how you use energy [1][2]. Metreleptin is a man-made version of this missing hormone, administered as a daily subcutaneous (under-the-skin) injection at home [3].

Because of the specialized nature of metreleptin and certain safety risks, it is only available in the United States through a strict, restricted program called a REMS (Risk Evaluation and Mitigation Strategy) program. Your doctor will need to enroll you in this program and provide specific training on how to handle and inject the medication safely.

Rather than just treating the symptoms (like high blood sugar), metreleptin addresses the root hormonal deficiency. Its benefits include:

  • Controlling Blood Sugar: It significantly improves insulin sensitivity, lowering HbA1c and fasting glucose levels [4][5].
  • Lowering Triglycerides: It helps the body process fats correctly, reducing the risk of life-threatening pancreatitis [5][4].
  • Reducing Liver Fat: It helps “clear” the fat that has built up in your liver (hepatic steatosis), reducing liver volume and preventing long-term scarring [6][7].
  • Curbing Hunger: By restoring the leptin signal to your brain, it can finally quiet the intense, constant hunger (hyperphagia) that many patients experience [4].

Managing the Underlying Cause

While metreleptin manages the metabolic “fire,” your doctors may also try to address the “spark” that caused the AGL. Your treatment path depends on your specific subtype:

If your AGL was caused by… The treatment focus is…
Autoimmune (Lawrence Syndrome) Managing the overactive immune system. Doctors may use immunosuppressants or corticosteroids, though these are used cautiously to avoid worsening metabolic issues [8][9].
Panniculitis-Associated Addressing the active inflammation. Steroids may be used during the inflammatory phase, but metreleptin remains essential for the resulting fat loss [8][10].
ICI-Induced (Cancer Treatment) Coordinating with your oncology team. Metreleptin is still used to treat the metabolic fallout, even if the cancer treatment triggered the condition [11][12].
Idiopathic (Unknown) Focused entirely on metabolic support (metreleptin) and regular screening for potential hidden triggers [12][13].

Risks and Safety Monitoring

Like any specialized medication, metreleptin requires careful monitoring.

  • Neutralizing Antibodies: In some cases, the body may develop antibodies that “neutralize” or block the drug’s effect [14]. If you notice your symptoms (like high blood sugar or extreme hunger) suddenly returning, your doctor will test for these [14].
  • Lymphoma Risk: There have been reports of T-cell lymphoma in patients with lipodystrophy. While hearing the word “lymphoma” is frightening, it is important to understand that this complication is extremely rare. Current research suggests it may be driven by the underlying autoimmune disease itself rather than the medication [15][16]. Your doctors will perform routine, non-invasive screenings to monitor your immune system so you do not have to worry about this alone.
  • Injection Site Reactions: Common side effects include redness or irritation where the medication is injected [17].

A Proactive Approach

The most important takeaway for AGL treatment is that early intervention matters. Starting metreleptin before severe complications like liver cirrhosis or kidney damage occur leads to significantly better long-term health outcomes [18][19]. Combined with a specialized diet—typically focused on strictly limiting simple sugars (like sodas and sweets) and carefully controlling fat intake to prevent triglyceride spikes—most patients can achieve much more stable health [5][20]. For help designing this diet, see Building Your Care Team.

Common questions in this guide

How does metreleptin treat AGL?
Metreleptin is a synthetic replacement for leptin, a hormone your body stops making when it loses fat tissue. It helps restore normal metabolism by controlling blood sugar, lowering triglycerides, clearing liver fat, and reducing intense hunger.
Is AGL treated differently depending on what caused it?
Yes, treatment plans are tailored to the underlying cause. While metreleptin manages the metabolic complications for all types of AGL, doctors may also use immunosuppressants for autoimmune-triggered AGL or coordinate with an oncology team if it was caused by cancer treatments.
What are the side effects of metreleptin for AGL?
The most common side effects are redness or irritation at the injection site. Doctors will also carefully monitor patients for rare complications, such as the development of neutralizing antibodies that can stop the medication from working effectively.
Will I need a special diet while treating AGL?
Yes, treating AGL typically requires combining medication with a specialized diet. This usually involves strictly limiting simple sugars and carefully controlling fat intake to prevent severe triglyceride spikes and protect organ function.
How soon will my symptoms improve after starting metreleptin?
Many patients notice a rapid decrease in their constant hunger after starting hormone replacement. Improvements in blood sugar and triglyceride levels also occur as insulin sensitivity improves, which your doctor will track through regular lab tests.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How soon after starting metreleptin can I expect to see improvements in my triglyceride levels and appetite?
  2. 2.If my AGL was triggered by an immune checkpoint inhibitor (ICI), will metreleptin still be effective for me?
  3. 3.How often will you be monitoring me for the development of neutralizing antibodies or other rare complications?
  4. 4.What is the plan for managing my underlying autoimmune condition alongside my metabolic treatments?
  5. 5.Is my dose of metreleptin based on my current body weight or my metabolic response?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    One-year metreleptin in Colombian sisters with congenital leptin deficiency.

    Yupanqui-Lozno H, Huertas-Quintero JA, Yupanqui-Velazco ME, et al.

    Adipocyte 2025; (14(1)):2508188 doi:10.1080/21623945.2025.2508188.

    PMID: 40415699
  2. 2

    Partial lipodystrophy: Clinical presentation and treatment.

    Mosbah H, Vatier C, Vigouroux C

    Annales d'endocrinologie 2024; (85(3)):197-200 doi:10.1016/j.ando.2024.05.015.

    PMID: 38871513
  3. 3

    Treatment Options for Lipodystrophy in Children.

    Mainieri F, Tagi VM, Chiarelli F

    Frontiers in endocrinology 2022; (13()):879979 doi:10.3389/fendo.2022.879979.

    PMID: 35600578
  4. 4

    Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy.

    Brown RJ, Valencia A, Startzell M, et al.

    The Journal of clinical investigation 2018; (128(8)):3504-3516.

    PMID: 29723161
  5. 5

    Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy.

    Brown RJ, Oral EA, Cochran E, et al.

    Endocrine 2018; (60(3)):479-489 doi:10.1007/s12020-018-1589-1.

    PMID: 29644599
  6. 6

    Leptin acutely increases hepatic triglyceride secretion in patients with lipodystrophy.

    Beghini M, Metz M, Baumgartner C, et al.

    Metabolism: clinical and experimental 2025; (169()):156261 doi:10.1016/j.metabol.2025.156261.

    PMID: 40204211
  7. 7

    Effects of Metreleptin in Pediatric Patients With Lipodystrophy.

    Brown RJ, Meehan CA, Cochran E, et al.

    The Journal of clinical endocrinology and metabolism 2017; (102(5)):1511-1519 doi:10.1210/jc.2016-3628.

    PMID: 28324110
  8. 8

    Corticosteroid-triggered acute skeletal muscle loss in lipodystrophy: A case report.

    Sasako T, Suzuki K, Odawara S, et al.

    Journal of diabetes investigation 2024; (15(6)):782-785 doi:10.1111/jdi.14158.

    PMID: 38372649
  9. 9

    An unusual case of acquired generalized lipodystrophy (panniculitis variety).

    Hill M, Weissman AS, Hirshburg J, et al.

    Pediatric dermatology 2024; (41(6)):1152-1155 doi:10.1111/pde.15668.

    PMID: 38887123
  10. 10

    A Report of Three Cases With Acquired Generalized Lipodystrophy With Distinct Autoimmune Conditions Treated With Metreleptin.

    Lebastchi J, Ajluni N, Neidert A, Oral EA

    The Journal of clinical endocrinology and metabolism 2015; (100(11)):3967-70 doi:10.1210/jc.2015-2589.

    PMID: 26390101
  11. 11

    Acquired Generalized Lipodystrophy: A New Cause of Anti-PD-1 Immune-Related Diabetes.

    Jehl A, Cugnet-Anceau C, Vigouroux C, et al.

    Diabetes care 2019; (42(10)):2008-2010 doi:10.2337/dc18-2535.

    PMID: 31434650
  12. 12

    Fatty Liver and Autoimmune Hepatitis: Two Forms of Liver Involvement in Lipodystrophies.

    Ribeiro A, Brandão JR, Cleto E, et al.

    GE Portuguese journal of gastroenterology 2019; (26(5)):362-369 doi:10.1159/000495767.

    PMID: 31559327
  13. 13

    A Novel Syndrome of Generalized Lipodystrophy Associated With Pilocytic Astrocytoma.

    Patni N, Alves C, von Schnurbein J, et al.

    The Journal of clinical endocrinology and metabolism 2015; (100(10)):3603-6 doi:10.1210/jc.2015-2476.

    PMID: 26252356
  14. 14

    Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy.

    Chan JL, Koda J, Heilig JS, et al.

    Clinical endocrinology 2016; (85(1)):137-49 doi:10.1111/cen.12980.

    PMID: 26589105
  15. 15

    A real-world pharmacovigilance assessment and literature review of lymphoma development in lipodystrophy.

    Brown RJ, Araujo-Vilar D, Walkovich KJ, et al.

    Frontiers in endocrinology 2025; (16()):1582715 doi:10.3389/fendo.2025.1582715.

    PMID: 40469440
  16. 16

    Diagnosis of acquired generalized lipodystrophy in a single patient with T-cell lymphoma and no exposure to Metreleptin.

    Esfandiari NH, Rubenfire M, Neidert AH, et al.

    Clinical diabetes and endocrinology 2019; (5()):4 doi:10.1186/s40842-019-0076-9.

    PMID: 30923630
  17. 17

    Adherence with metreleptin therapy and health self-perception in patients with lipodystrophic syndromes.

    Vatier C, Kalbasi D, Vantyghem MC, et al.

    Orphanet journal of rare diseases 2019; (14(1)):177 doi:10.1186/s13023-019-1141-2.

    PMID: 31300002
  18. 18

    Effects of Metreleptin in Patients With Generalized Lipodystrophy Before vs After the Onset of Severe Metabolic Disease.

    Brush M, Auh S, Cochran E, et al.

    The Journal of clinical endocrinology and metabolism 2025; (110(4)):e1051-e1061 doi:10.1210/clinem/dgae335.

    PMID: 38757950
  19. 19

    Metreleptin Treatment in a Boy with Congenital Generalized Lipodystrophy due to Homozygous c.465_468delGACT (p.T156Rfs*8) Mutation in the BSCL2 Gene: Results From the First-year

    Özalkak Ş, Demiral M, Ünal E, et al.

    Journal of clinical research in pediatric endocrinology 2023; (15(3)):329-333 doi:10.4274/jcrpe.galenos.2022.2022-1-25.

    PMID: 35735786
  20. 20

    A Novel Generalized Lipodystrophy-Associated Progeroid Syndrome Due to Recurrent Heterozygous LMNA p.T10I Mutation.

    Hussain I, Patni N, Ueda M, et al.

    The Journal of clinical endocrinology and metabolism 2018; (103(3)):1005-1014 doi:10.1210/jc.2017-02078.

    PMID: 29267953

This page provides educational information about treatments for Acquired Generalized Lipodystrophy (AGL). Always consult your endocrinologist or care team before making changes to your medication, injection routine, or diet.

Get notified when new evidence is published on Acquired generalized lipodystrophy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.